“In vivo and ex vivo Magnetic Resonance Spectroscopy of the Infarct and the Subventricular Zone in Experimental Stroke” by E. Jiménez-Xarrié, M. Davila, S. Gil-Perotín, A. Jurado-Rodríguez, A.P. Candiota, R. Delgado-Mederos, S. Lope-Piedrafita, J.M. García-Verdugo, C. Arús, J. Martí-Fàbregas. Journal of Cerebral Blood Flow & Metabolism, 2015, 35:828–834. DOI: 10.1038/jcbfm.2014.257
Ischemic stroke changes the metabolic pattern in the infarct area and also in other regions such as the ipsilateral subventricular zone (SVZi) where neural progenitor cells (NPCs) proliferation is enhanced in the mammalian and human brains. Magnetic resonance spectroscopy (MRS) provides metabolic information in vivo. With regard to NPCs proliferation, a resonance at 1.28 ppm has been described as an in vivo MRS biomarker of NPCs in the hippocampus of rats and humans. Continue reading In vivo MRS and ex vivo HRMAS in an Ischemic Rat Stroke Model
“Real-time assessment of 13C metabolism reveals an early lactate increase in the brain of rats with acute liver failure” by Laia Chavarria, Jordi Romero-Giménez, Eva Monteagudo, Silvia Lope-Piedrafita, Juan Cordoba. NMR in Biomedicine (2014) 28:17-23. DOI: 10.1002/nbm.3226
Intracranial hypertension is a severe complication of acute liver failure (ALF) secondary to brain edema. The pathogenesis of cerebral edema in ALF is not clear, but seems to be related to energy metabolism in which lactate may have an important role. The aim of this study was to follow the synthesis of brain lactate using a novel in vivo metabolic technology in a rat model of ALF. Continue reading Hyperpolarized 13C Magnetic Resonance in Acute Liver Failure Rats
“A new ex vivo method to evaluate the performance of candidate MRI contrast agents: a proof-of-concept study” by Candiota A.P., Acosta M., Simões R.V., Delgado-Goñi T., Lope-Piedrafita S., Irure A., Marradi M., Bomatí-Miguel O., Miguel-Sancho N., Abasolo I., Schwartz S. Jr., Santamaría J., Penadés S., Arús C. J Nanobiotechnology 2014 12:12. DOI: 10.1186/1477-3155-12-12.
A new method has been developed for selecting MRI contrast agents with better expected in vivo performance. This method requires only a very small amount of contrast agent (e.g. 5 nmols/animal, 800 times less than the quantity necessary for in vivo administration) and allows to carry out a more rationally informed candidate selection, avoiding unnecessary in vivo and toxicology tests for the ex vivo poorly performing substances, consequently reducing animal needs, material consumption and overall costs. Continue reading Ex vivo method to evaluate MRI contrast agents